LinkedIn Profile

Access Mesoblast Limited historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Sector Industry
nasdaq:meso 678282 Sep 4th, 2021 12:00AM Mesoblast Limited 6.7K 86.00 Open Biotechnology Sep 3rd, 2021 10:48PM Sep 3rd, 2021 10:48PM Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced chronic heart failure, and • MPC-06-ID for chronic low back pain due to degenerative disc disease. The US FDA has accepted for priority review Mesoblast's BLA to seek approval of RYONCIL to treat acute GVHD in children and set a PDUFA action date of September 30, 2020. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast’s approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing reviewof independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection. Open Cell-based therapies, cellular medicines, Mesenchymal Lineage Adult Stem Cells, regenerative medicine, COVID-19, Chronic Heart Failure, Graft Versus Host Disease, Chronic Low Back Pain, Rheumatoid Arthritis Open Level 38, 55 Collins St Melbourne VIC AU 3000
nasdaq:meso 678282 Sep 3rd, 2021 12:00AM Mesoblast Limited 6.7K 86.00 Open Biotechnology Sep 3rd, 2021 12:32PM Sep 3rd, 2021 12:32PM Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced chronic heart failure, and • MPC-06-ID for chronic low back pain due to degenerative disc disease. The US FDA has accepted for priority review Mesoblast's BLA to seek approval of RYONCIL to treat acute GVHD in children and set a PDUFA action date of September 30, 2020. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast’s approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing reviewof independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection. Open Cell-based therapies, cellular medicines, Mesenchymal Lineage Adult Stem Cells, regenerative medicine, COVID-19, Chronic Heart Failure, Graft Versus Host Disease, Chronic Low Back Pain, Rheumatoid Arthritis Open Level 38, 55 Collins St Melbourne VIC AU 3000
nasdaq:meso 678282 Sep 2nd, 2021 12:00AM Mesoblast Limited 6.7K 86.00 Open Biotechnology Sep 2nd, 2021 10:14AM Sep 2nd, 2021 10:14AM Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced chronic heart failure, and • MPC-06-ID for chronic low back pain due to degenerative disc disease. The US FDA has accepted for priority review Mesoblast's BLA to seek approval of RYONCIL to treat acute GVHD in children and set a PDUFA action date of September 30, 2020. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast’s approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing reviewof independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection. Open Cell-based therapies, cellular medicines, Mesenchymal Lineage Adult Stem Cells, regenerative medicine, COVID-19, Chronic Heart Failure, Graft Versus Host Disease, Chronic Low Back Pain, Rheumatoid Arthritis Open Level 38, 55 Collins St Melbourne VIC AU 3000
nasdaq:meso 678282 Sep 1st, 2021 12:00AM Mesoblast Limited 6.7K 86.00 Open Biotechnology Sep 1st, 2021 09:50AM Sep 1st, 2021 09:50AM Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced chronic heart failure, and • MPC-06-ID for chronic low back pain due to degenerative disc disease. The US FDA has accepted for priority review Mesoblast's BLA to seek approval of RYONCIL to treat acute GVHD in children and set a PDUFA action date of September 30, 2020. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast’s approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing reviewof independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection. Open Cell-based therapies, cellular medicines, Mesenchymal Lineage Adult Stem Cells, regenerative medicine, COVID-19, Chronic Heart Failure, Graft Versus Host Disease, Chronic Low Back Pain, Rheumatoid Arthritis Open Level 38, 55 Collins St Melbourne VIC AU 3000
nasdaq:meso 678282 Aug 31st, 2021 12:00AM Mesoblast Limited 6.7K 86.00 Open Biotechnology Aug 31st, 2021 09:43AM Aug 31st, 2021 09:43AM Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced chronic heart failure, and • MPC-06-ID for chronic low back pain due to degenerative disc disease. The US FDA has accepted for priority review Mesoblast's BLA to seek approval of RYONCIL to treat acute GVHD in children and set a PDUFA action date of September 30, 2020. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast’s approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing reviewof independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection. Open Cell-based therapies, cellular medicines, Mesenchymal Lineage Adult Stem Cells, regenerative medicine, COVID-19, Chronic Heart Failure, Graft Versus Host Disease, Chronic Low Back Pain, Rheumatoid Arthritis Open Level 38, 55 Collins St Melbourne VIC AU 3000
nasdaq:meso 678282 Aug 30th, 2021 12:00AM Mesoblast Limited 6.7K 86.00 Open Biotechnology Aug 30th, 2021 10:06AM Aug 30th, 2021 10:06AM Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced chronic heart failure, and • MPC-06-ID for chronic low back pain due to degenerative disc disease. The US FDA has accepted for priority review Mesoblast's BLA to seek approval of RYONCIL to treat acute GVHD in children and set a PDUFA action date of September 30, 2020. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast’s approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing reviewof independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection. Open Cell-based therapies, cellular medicines, Mesenchymal Lineage Adult Stem Cells, regenerative medicine, COVID-19, Chronic Heart Failure, Graft Versus Host Disease, Chronic Low Back Pain, Rheumatoid Arthritis Open Level 38, 55 Collins St Melbourne VIC AU 3000
nasdaq:meso 678282 Aug 29th, 2021 12:00AM Mesoblast Limited 6.7K 86.00 Open Biotechnology Aug 29th, 2021 04:11PM Aug 29th, 2021 04:11PM Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced chronic heart failure, and • MPC-06-ID for chronic low back pain due to degenerative disc disease. The US FDA has accepted for priority review Mesoblast's BLA to seek approval of RYONCIL to treat acute GVHD in children and set a PDUFA action date of September 30, 2020. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast’s approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing reviewof independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection. Open Cell-based therapies, cellular medicines, Mesenchymal Lineage Adult Stem Cells, regenerative medicine, COVID-19, Chronic Heart Failure, Graft Versus Host Disease, Chronic Low Back Pain, Rheumatoid Arthritis Open Level 38, 55 Collins St Melbourne VIC AU 3000
nasdaq:meso 678282 Aug 28th, 2021 12:00AM Mesoblast Limited 6.7K 87.00 Open Biotechnology Aug 28th, 2021 02:44PM Aug 28th, 2021 02:44PM Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced chronic heart failure, and • MPC-06-ID for chronic low back pain due to degenerative disc disease. The US FDA has accepted for priority review Mesoblast's BLA to seek approval of RYONCIL to treat acute GVHD in children and set a PDUFA action date of September 30, 2020. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast’s approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing reviewof independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection. Open Cell-based therapies, cellular medicines, Mesenchymal Lineage Adult Stem Cells, regenerative medicine, COVID-19, Chronic Heart Failure, Graft Versus Host Disease, Chronic Low Back Pain, Rheumatoid Arthritis Open Level 38, 55 Collins St Melbourne VIC AU 3000
nasdaq:meso 678282 Aug 27th, 2021 12:00AM Mesoblast Limited 6.7K 87.00 Open Biotechnology Aug 27th, 2021 10:30AM Aug 27th, 2021 10:30AM Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced chronic heart failure, and • MPC-06-ID for chronic low back pain due to degenerative disc disease. The US FDA has accepted for priority review Mesoblast's BLA to seek approval of RYONCIL to treat acute GVHD in children and set a PDUFA action date of September 30, 2020. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast’s approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing reviewof independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection. Open Cell-based therapies, cellular medicines, Mesenchymal Lineage Adult Stem Cells, regenerative medicine, COVID-19, Chronic Heart Failure, Graft Versus Host Disease, Chronic Low Back Pain, Rheumatoid Arthritis Open Level 38, 55 Collins St Melbourne VIC AU 3000
nasdaq:meso 678282 Aug 26th, 2021 12:00AM Mesoblast Limited 6.6K 87.00 Open Biotechnology Aug 26th, 2021 09:05AM Aug 26th, 2021 09:05AM Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced chronic heart failure, and • MPC-06-ID for chronic low back pain due to degenerative disc disease. The US FDA has accepted for priority review Mesoblast's BLA to seek approval of RYONCIL to treat acute GVHD in children and set a PDUFA action date of September 30, 2020. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast’s approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing reviewof independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection. Open Cell-based therapies, cellular medicines, Mesenchymal Lineage Adult Stem Cells, regenerative medicine, COVID-19, Chronic Heart Failure, Graft Versus Host Disease, Chronic Low Back Pain, Rheumatoid Arthritis Open Level 38, 55 Collins St Melbourne VIC AU 3000

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.